ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026
Vascular and inflammatory biomarkers linked to neurocognition in Ugandan youth with perinatal HIV on dolutegravir.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesTo examine associations of immune biomarkers with neurocognition among Ugandan Youth living with Perinatally acquired HIV (YPHIV) virally suppressed on dolutegravir (DTG) versus Youth Without HIV (YWoH).
methodsIn this cross-sectional study of 101 age- and sex-matched youth in Kampala, Uganda (49 YPHIV, 52 YWoH), neurocognition was assessed using NeuroScreen. Biomarkers were measured using LEGENDplex™ and ELISA. Group differences were assessed using Wilcoxon rank-sum tests. Associations were evaluated using Spearman correlations and multivariable linear regression.
resultsMedian age was 16.9 years [IQR 15.1-17.1]. YPHIV performed worse across all neurocognitive domains (P ≤ 0.035). IFAB, MIP-3α, and RANTES were higher among YPHIV (P ≤ 0.024). In adjusted YPHIV models, myeloperoxidase was associated with worse processing speed (β = -3.24, 95% CI = -4.89, -1.58), learning and memory (β = -3.53, 95% CI = -6.48, -0.59), and global z-scores (β = -1.64, 95% CI = -2.78, -0.51); soluble CD14 (sCD14) with worse processing speed (β = -0.78, 95% CI = -1.55, -0.01); β-d-Glucan (BDG) with worse learning and memory (β = -0.35, 95% CI = -0.68, -0.03).
conclusionsUgandan YPHIV demonstrated worse neurocognitive performance. Biomarkers linked to HIV-related mortality and cardiovascular disease (MPO, sCD14, BDG) were associated with poorer performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.